JANSSEN VACCINES & PREVENTION B.V.

Janssen Vaccines & Prevention B.V. specializes in advanced research and development of biotechnological and life science-based medical countermeasures, with a focused expertise in vaccine design, virology, and immunological innovation. Their technical capabilities center on the development of multivalent viral vaccines, particularly against hemorrhagic fever pathogens such as Ebola and Marburg, leveraging cutting-edge platforms in antigen formulation, viral vector engineering, and immune response modulation. The contractor demonstrates deep proficiency in preclinical and translational vaccine development, with a track record of advancing complex filovirus vaccine candidates through early-stage innovation toward clinical readiness. Their work integrates molecular biology, structural virology, and high-throughput screening methodologies to address high-consequence infectious disease threats. The organization maintains a consistent relationship with the Department of Health and Human Services, delivering mission-critical research and development services aimed at public health preparedness and biodefense. Their engagements with HHS typically involve advanced vaccine development programs under federal biomedical research initiatives, often aligned with BARDA or NIH priorities for pandemic response and emerging pathogen mitigation. Their primary industry focus lies within biotechnology research (NAICS 541711) and broader life sciences R&D (NAICS 541712), positioning them as a specialized contractor in the federal biodefense and infectious disease vaccine market. They operate at the intersection of academic innovation and government-funded translational science, serving as a technical partner for high-risk, high-reward vaccine platforms. Janssen Vaccines & Prevention B.V. is structured as a corporate entity based in Leiden, Netherlands, with no publicly disclosed U.S. government certifications. While their physical presence is international, their contract activity is exclusively oriented toward U.S. federal research funding streams, indicating a strategic role as a foreign contractor supporting critical U.S. public health objectives through specialized scientific collaboration.